updated 9/9/2010 12:15:53 AM ET 2010-09-09T04:15:53

EMERYVILLE, Calif., Sept. 8, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference will take place September 12-15, 2010 at the Boston Convention and Exhibition Center in Boston, MA.

The presentations will highlight new data developed from studies of NovaBay's Aganocide® family of compounds, which have shown to be highly effective against bacteria, including multi-drug resistant strains (e.g. MRSA), viruses and fungi in preclinical testing. Additionally, NovaBay's lead Aganocide, NVC-422, has recently demonstrated efficacy in a 129 patient dose-ranging Phase 2 clinical trial for the treatment of impetigo, a highly contagious skin infection affecting over 1.3 million patients in the U.S. annually.

Ron Najafi, chairman and CEO of NovaBay, said, "These presentations illustrate the anti-infective versatility of our Aganocide compounds and NovaBay's commitment to addressing the growing global crisis of antibiotic resistance by developing and commercializing an extensive pipeline of first-in-class, anti-infective compounds that are designed to treat infections without causing resistance."

NovaBay's pipeline of Aganocide compounds is being studied in numerous preclinical and clinical programs. Four (4) clinical trials of the company's lead Aganocide drug candidate are under way in impetigo, a highly contagious skin infection; urinary catheter-blockage and encrustation and associated infection; conjunctivitis (pink eye); and acne.

Poster session details are as follows:

Poster Title: V-420/444 -In Vitro Activity of N-Chlorotaurine (NCT), N-Monochloro-2,2-Dimethyltaurine (NVC-612) and N,N-Dichloro-2,2-Dimethyltaurine (NVC-422) against Influenza Viruses

Date: Sunday, Sept. 12

Time: 11:30 a.m. to 1:30 p.m.

Place: Exhibit Hall B1

Poster Title: K-2199/220Efficacy of NVC-422, a Novel Derivative of N-Chlorotaurine, in Controlling Crystalline Proteus mirabilis Biofilm Formation on Urinary Catheters

Date: Wednesday, Sept. 15

Time: 9 a.m. to 11 a.m.

Place: Exhibit Hall B1

Poster Title: F1-2119-NVC-422: Towards Developing Preclinical Infected Tissue Models

Date: Wednesday, Sept. 15

Time: 9 a.m. to 11 a.m.

Place: Exhibit Hall B1

Poster Title: F1-2118/137-Anticoagulant Effects of N-Chlorotaurine and the Analogs N-Monochloro-2-2-Dimethyltaurine and N,N-Dichloro-2,2-Dimethyltaurine

Date: Wednesday, Sept. 15

Time: 9 a.m. to 11 a.m.

Place: Exhibit Hall B1

About Aganocides

NovaBay's Aganocide® compounds are novel, synthetic N-chlorinated antimicrobial molecules specifically designed and developed to mimic the body's natural defense against infection. The Aganocide compounds maintain biological activities while demonstrating improved stability over the naturally occurring N-chlorinated antimicrobial molecules. In preclinical testing, NovaBay's Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi. In a Phase 2a, human proof-of-concept clinical study, NovaBay's lead Aganocide compound demonstrated efficacy in treating impetigo, including cases caused by MRSA.  NovaBay's Aganocide compounds have the potential to deliver the same or better efficacy than antibiotics, and to address the growing problem of antibiotic resistance by employing a novel mechanism of action.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay also has an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com .

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release of NovaBay's expectations regarding the Aganocides possessing the characteristics of a broad spectrum antimicrobial agent that carries little potential for resistance and the development and commercialization of its Aganocide compounds through collaborations with corporate partners are forward-looking statements. Other risks relating to NovaBay and its Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Quarterly Report on Form 10-Q for the period ended June 30, 2010, under the caption "Risk Factors" in Item 1A of Part II of that report, filed with the Securities and Exchange Commission on August 12, 2010. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com